WASHINGTON, DC - (NewMediaWire) - September 23, 2015 - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in cannabis formulation-based drug development, today announced that the world recognized advocate for peace and social justice, accomplished legislator, political leader, former chairman of the US House Armed Services Committee, and President of the Dellums Institute: Partners for Global Health + Justice, Hon. Ronald V. Dellums has been appointed the Chairman of the new International Government Affairs Board of CBIS.
As a member and Chairman of the House Armed Services Committee, Mr. Dellums used his leadership to question US policy and brought about the first real strategic debates on military policy in the post-Cold War world. He was a key member of the first congressional group to visit the Soviet Union and used that visit to engage his counterparts in discussions about the need to find lasting solutions for peace. He served on numerous other committees, including as chairman of the DC Committee, whose efforts resulted in Home Rule for the District of Columbia. Under his leadership, the DC Committee focused on the problems of cities and addressed issues of the unfunded pension liability of city workers, affordable housing, homelessness and mental health, the problems of urban infant mortality, the negative impacts on local tax bases of public and non-profit development (hospitals, universities, etc.), and the financial inability of city governments to finance adequate and appropriate services for their residents.
As a private citizen, Mr. Dellums was Chair of President Clinton's Presidential Advisory Council on HIV and AIDS and remained on the Council at the request of President George W. Bush. Mr. Dellums initiated the legislation for a Global AIDS Fund that now, as the President's Emergency Plan for AIDS Relief (PEPFAR) provides billions of dollars for HIV prevention and treatment, AIDS drug development, and HIV/AIDS health services research. As president of Healthcare International Management, Mr. Dellums worked closely with the newly democratic South African government to develop affordable healthcare and bring awareness, prevention and treatment in response to the AIDS epidemic. He helped secure $100 million from the Bristol Myers Squibb Pharmaceutical Company that funded HIV and AIDS research and education in South Africa, Swaziland, Lesotho, Botswana and Namibia. Mr. Dellums has a deep commitment to the health needs of communities and understands the role that both education and research play in the development of communities. For his work to improve the lives of people living with HIV and AIDS in Africa and around the world, Mr. Dellums was awarded an honorary doctorate from the National School of Public Health of the Republic of South Africa.
Mr. Dellums has a long and illustrious career in public service, serving first on the Berkeley City Council and then for 27 years as a member of the United States Congress. He was a founding member of the Congressional Black Caucus that continues to support and advance the agenda of urban housing and development, education, transportation, and health care and urban development. Following his service in the US Congress, Mr. Dellums returned to his hometown to serve as the Mayor of Oakland, California.
"This is an exciting opportunity for me to work with Mr. Dabney and the CBIS Team in order to advance healthcare treatments for people suffering from HIV/AIDS and other conditions. I look forward to assisting the team with focused governmental affairs and policy agendas at the state, federal, and international levels," said Mr. Dellums.
"We now have yet another cornerstone that will help us take the company to the next level. Mr. Dellums will join our well-respected and accomplished advisory board and will help develop robust governmental affairs and policy focuses for CBIS," stated, Mr. Dabney.
From his first days in Congress, Mr. Dellums led the fight against apartheid in South Africa and authored bills to withhold support from the Apartheid South African regime. In 1986, it was the Dellums Amendment, a bill that passed the House, which led to divestment from South Africa with Congress over-riding a Reagan presidential veto. This divestment pressure helped the anti-apartheid movement in South Africa win the release of Nelson Mandela and his election as President of a democratic South Africa. For this work, the post-apartheid government of South Africa awarded Mr. Dellums the Distinguished Order of the Companions of O.R. Tambo.
Mr. Dellums chaired the Joint Center for Political and Economic Studies' Commission on the Status of Boys and Men of Color, which pioneered addressing the structural barriers to the physical, emotional, and social advancement of boys and men of color (the "Dellums Commission"). The Dellums Commission inspired change efforts in different parts of the nation, including the development of Kings County's (Seattle) Office of Equity and Social Justice in 2006, which serves as a model for other agencies, including the City of Oakland's new Department of Race and Equity. The Dellums Commission also influenced "My Brother's Keeper" an initiative of President Obama.
Throughout his career, Mr. Dellums has brought parties together, removed obstacles, and gotten things done. He has advised world leaders on sensitive matters of global peace and national security in the Middle East, Cuba, South Africa, Haiti, and Bosnia, achieving important outcomes for the international community. At a local level, when the Port of Oakland dredging was stalled, he brought the parties together and found solutions acceptable to the previously warring interests of the Port, the environmental community, labor, and the Corps of Engineers. Similarly, Mr. Dellums was instrumental in resolving countless labor disputes, including an intractable garbage dispute between Waste Management and the Teamsters, as well as a threatened strike of 1,000 Port truck drivers.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.